Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...

While we don’t see this purchase as significantly affecting Merck’s wide moat, it does help diversify the company's late-stage pipeline. Merck Posts Solid Q4 Results, but Heavy Investments in ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Keytruda, approved for several types of cancer, alone accounts for around 50% of the company’s pharmaceutical sales. The drug ...

The 21st century pharmaceutical and biotech ... health was a comparatively late development. Merck in Germany was possibly the earliest company to move in this direction. Originating as a pharmacy ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

Merck & Company (MRK) Company Description: Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company ...

(Reuters) - Merck has acquired Modifi Biosciences for ... New Haven, Connecticut-based Modifi is a pre-clinical stage company, which develops cancer therapies that aim to selectively kill cancer ...